GSK1904529A
1089283-49-7
99%
2026-07-01
Coenzymes,Inhibito,Enzymes,Zymogens,Substrates,Native Microorganism Creatine Amidinohydrolase
-
Product Description
-
Seller Information
-
Description
ProductName GSK1904529A Cat No CEI-0072 Description GSK1904529A can inhibit IGF-IR and IR with IC50 of 27 nM and 25 nM. CAS No 1089283-49-7 Molecular Weight 851.96 Purity >99% Storage 2 years at -20centigrade Powder Targets IGF-IR, IR Molecular Formula C44H47F2N9O5S Chemical Name N-(2,6-difluorophenyl)-5-(3-(2-(5-ethyl-2-methoxy-4-(4-(4-(methylsulfonyl)piperazin-1-yl)piperidin-1-yl)phenylamino)pyrimidin-4-yl)H-imidazo[1,2-a]pyridin-2-yl)-2-methoxybenzamide Solubility DMSO 124 mg/mL Water In vitro GSK1904529A selectively inhibits IGF-IR(insulin-like growth factor-I receptor) and IR (insulin receptor) with IC50 of 27 nM and 25 nM. GSK1904529A blocks receptor autophosphorylation and downstream signaling, leading to cell cycle arrest. For cell lines As insulin-like growth factor-I receptor is involved in development of many types of tumors, including prostate, colon, breast, pancreatic, ovarian, and sarcomas, GSK1904529A can inhibit many cancer cell lines. GSK1904529A can inhibits the proliferation of cell lines derived from solid and hematologic malignancies, with multiple myeloma and Ewings sarcoma cell lines being most sensitive. In vivo Oral administration of GSK1904529A decreases the growth of human tumor xenografts in mice, consistent with a reduction of IGF-IR phosphorylation in tumors. category Heterocyclic Compound(c1111) cas_num 1089283-49-7 Basic Info-
Product Name:
GSK1904529A
Other Name:GSK1904529A;GSK1904529A : IGF-IR, IGF-IIR inhibitor;N-(2,6-Difluorophenyl)-5-[3-[2-[[5-ethyl-2-(methyloxy)-4-[4-[4-(methylsulfonyl)-1-piperazinyl]-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]imidazo[1,2-a]pyridin-2-yl]-2-(methyloxy)benzamide;GSK 4529;N-(2,6-difluorophenyl)-5-(3-(2-(5-ethyl-2-methoxy-4-(4-(4-(methylsulfonyl)piperazin-1-yl)piperidin-1-yl)phenylamino)pyrimidin-4-yl)H-imidazo[1,2-a]pyridin-2-yl)-2-methoxybenzamide;N-(2,6-Difluorophenyl)-5-[3-[2-[[5-ethyl-2-(methyloxy)-4-[4-[4-(methylsulfonyl)-1-piperazinyl]-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]imidazo[1,2-a]pyridin-2-yl]-2-(methyloxy)benzamide GSK 1904529A;GSK1904529A, >=98%;IGF-IR, IGF-IIR inhibitor
CAS No.:1089283-49-7
Molecular Formula:C44H47F2N9O5S
InChIKeys:MOSKATHMXWSZTQ-UHFFFAOYSA-N
Molecular Weight:851.98
Exact Mass:851.338867
DSSTox ID:DTXSID70648776
Categories:
Characteristics-
PSA:
155
XLogP3:6.8
Density:1.39
Refractive Index:1.672
Hazard IdentificationClassification of the substance or mixture
no data available
GHS label elements, including precautionary statements
Pictogram(s) no data available Signal word no data available
Hazard statement(s) no data available
Precautionary statement(s) Prevention no data available
Response no data available
Storage no data available
Disposal no data available
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
Coenzymes,Inhibito,Enzymes,Zymogens,Substrates,Native Microorganism Creatine Amidinohydrolase
-
Location:
Shirley, New York 11967, USA
-
Payment Terms:
TT against copy of documents,D/P
-
Average lead Time:
15
-
Total Annual Revenue:
$1 million-$2.5 million
-
Year of Establishment:
2004
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product